Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

Nurix Therapeutics said new and updated clinical data for investigational oral BTK degrader bexobrutideg (NX-5948) from its ongoing Phase 1a/1b study will be presented at the ASH Annual Meeting on December 12–15, 2026. The announcement provides no clinical results or efficacy figures.

Analysis

This is a catalyst-calendar update, not evidence of clinical de-risking: the announcement provides no efficacy, safety, cohort-size, or durability data. The stock’s near-term sensitivity is therefore more likely to reflect expectations and positioning than a changed estimate of bexobrutideg’s commercial value. The key differentiation to test at ASH is whether degrading BTK produces clinically meaningful activity in patients whose disease has progressed on BTK inhibitors, without a tolerability trade-off; absent that, the mechanism alone should not support a premium over inhibitor-based approaches.

The immediate risk is a run-up in NRIX into the December 12–15 meeting followed by volatility or a sell-the-news reaction. Over 1–3 months, the poster’s cohort maturity, response durability, and safety detail should determine whether expectations move; over 6–18 months, development progress and the ability to establish a differentiated treatment position matter more than this presentation announcement. The contrarian point is that investors may price the word “updated” as a substantive clinical inflection before seeing the data. No directional edge is established yet; reassess against the full abstract and poster.

Key Decisions for Investors

• Do not buy NRIX solely on this announcement. Put the ASH abstract/poster release on the catalyst calendar and verify patient numbers, prior BTK-inhibitor exposure, response depth and duration, discontinuations, and adverse events before changing the thesis.
• If NRIX rallies materially before the data without new clinical detail, consider reducing event exposure rather than assuming the move is validated; avoid an unhedged short because positive data could reprice the clinical optionality sharply.
• After the poster is available, consider a defined-risk NRIX call spread only if results show credible activity in the relevant resistant population, acceptable safety, and enough follow-up to assess durability—and only after checking implied volatility and the market’s embedded expectations.
• Falsify a constructive read if the update is based on very small or immature cohorts, fails to show durable responses, reveals tolerability concerns, or is followed by management narrowing development expectations.